First or Corresponding Author

1. Lin YT, Chan YJ, Chiu CH, Lin ML, Yu KW, Wang FD, Liu CY. Tigecycline and colistin susceptibility of Chryseobacterium meningosepticum isolated from blood in Taiwan. Int J Antimicrob Agents. 2009; 34(1):100-1. (2021 IF=15.441, Rank 11/94, infectious diseases)

2. Lin YT, Chiu CH, Chan YJ, Lin ML, Yu KW, Wang FD, Liu CY. Clinical and microbiological analysis of Elizabethkingia meningoseptica bacteremia in adult patients in Taiwan. Scand J Infect Dis. 2009; 41(9):628-34. (2021 IF=5.838, Rank 31/94, infectious diseases)

3. Lin YT, Chen TL, Siu LK, Hsu SF, Fung CP. Clinical and microbiological characteristics of community-acquired thoracic empyema or complicated parapneumonic effusion caused by Klebsiella pneumoniae in Taiwan. Eur J Clin Microbiol Infect Dis. 2010; 29(8):1003-10. (2021 IF=5.103, Rank 49/136, microbiology)

4. Lin YT, Jeng YY, Chen TL, Fung CP. Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: Clinical and microbiological characteristics in Taiwan, 2001-2008. BMC Infect Dis. 2010; 10:307. (2021 IF=3.670, Rank 60/94, infectious diseases)

5. Lin YT, Jeng YY, Lin ML, Yu KW, Wang FD, Liu CY. Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia. J Microbiol Immunol Infect. 2010; 43(6):498-505. (2021 IF=10.273, Rank 17/136, microbiology)

6. Lin YT, Liu CJ, Fung CP, Tzeng CH. Nosocomial Klebsiella pneumoniae bacteraemia in adult cancer patients-characteristics of neutropenic and non-neutropenic patients. Scand J Infect Dis. 2011; 43(8):603-8. (2021 IF=15.441, Rank 11/94, infectious diseases)

7. Lin YT, Liu CJ, Chen TJ, Yeh YC, Wu HS, Tseng CP, Wang FD, Tzeng CH, Fung CP. Pyogenic liver abscess as the initial manifestation of underlying hepatocellular carcinoma. Am J Med. 2011; 124(12):1158-64. (2021 IF=5.928, Rank: 36/172, medicine, general & internal)

8. Lin YT, Siu LK, Lin JC, Chen TL, Tseng CP, Yeh KM, Chang FY, Fung CP. Seroepidemiology of Klebsiella pneumoniae colonizing the intestinal tract of healthy Chinese and overseas Chinese adults in Asian countries. BMC Microbiol. 2012; 12:13 (2021 IF=4.465, Rank 60/136, microbiology)

9. Wu HS, Wang FD, Tseng CP, Wu TH, Lin YT*, Fung CP. Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan. J infect. 2012; 64(2):162-8. (*corresponding author, 2021 IF=38.637, Rank 4/94, infectious diseases)

10. Lin YT, Liu CJ, Chen TJ, Fung CP. Long-term mortality of patients with septic ocular or central nervous system complications from pyogenic liver abscess: A population-based study. PLoS ONE. 2012; 7(3):e33978. (2021 IF=3.752, Rank 29/73, multidisciplinary sciences)

11. Lin YT, Fung CP. Pyogenic liver abscess in the elderly: What we have learned? J Chin Med Assoc. 2012; 75(4):139-40. (2021 IF=3.396, Rank: 71/172, medicine, general & internal)

12. Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT*, Fung CP. Risk of cancer among patients with herpes zoster infection: a population-based study. CMAJ. 2012; 16;184(15):E804-9. (*corresponding author, 2021 IF=16.882, Rank 13/172, medicine, general & internal)

13. Tseng CP, Wu HS, Wu TH, Lin YT*, Fung CP. Clinical characteristics and outcome of patients with community-onset Klebsiella pneumoniae bacteremia requiring intensive care. J Microbiol Immunol Infect. 2013; 46(3):217-23. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

14. Lin YT, Wang FD, Wu PF, Fung CP. Klebsiella pneumoniae liver abscess in diabetic patients: association of glycemic control with the clinical characteristics. BMC Infect Dis. 2013; 13:56. (2021 IF=3.670, Rank 60/94, infectious diseases)

15. Lin YT, Liu CJ, Yeh YC, Chen TJ, Fung CP. Ampicillin and amoxicillin use and the risk of Klebsiella pneumoniae liver abscess in Taiwan. J Infect Dis. 2013; 208(2): 211-7. (2021 IF=7.759, Rank: 19/94, Infectious Diseases)

16. Liu BH, Duh RW, Lin YT*, Yang TL, Fung CP, TSAR Hospitals. A multicenter surveillance of antimicrobial resistance in Serratia marcescens in Taiwan. J Microbiol Immunol Infect. 2014;47(5):387-93. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

17. Lin YT, Wang FD, Chan YJ, Fu YC, Fung CP. Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan. BMC Infect Dis. 2014; 14:1. (2021 IF=3.670, Rank 60/94, infectious diseases)

18. Lin YT, Tseng KY, Yeh YC, Yang FC, Fung CP, Chen NJ. TREM-1 promotes survival during Klebsiella pneumoniae liver abscess in mice. Infect Immun. 2014; 82(3):1335-42. (2021 IF=3.621, Rank 62/94, infectious diseases)

19. Lin YT, Huang YW, Liou RS, Chang YC, Yang TC. MacABCsm, an ABC-type tripartite efflux pump of Stenotrophomonas maltophilia involved in drug resistance, oxidative and envelope stress tolerances and biofilm formation. J Antimicrob Chemother. 2014; 69(12):3221-6. (2021 IF=5.758, Rank 54/279, Pharmacology & Pharmacy)

20. Lin YT*, Wang YP, Wang FD, Fung CP. Community-onset Klebsiella pneumoniae pneumonia in Taiwan: clinical features of the disease and associated microbiological characteristics of isolates from pneumonia and nasopharynx. Front Microbiol. 2015; 9:122. (*corresponding author, 2021 IF=6.064, Rank: 34/136, microbiology)

21. Chang YY, Chuang YC, Siu LK, Wu TL, Lin JC, Lu PL, Wang JT, Wang LS, Lin YT*, Huang LJ, Fung CP. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: A nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015 ;48(2):219-25. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

22. Wu PF, Chang YY, Lin YT*, Wang FD, Chan YJ, Fung CP. Clinical characteristics and economic consequence of Klebsiella pneumoniae liver abscess in Taiwan. J Microbiol Immunol Infect. 2015; 48(2):190-7. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

23. Wang YP, Liu CJ, Chen TJ, Lin YT*, Fung CP. Proton pump inhibitor use significantly increases the risk of cryptogenic liver abscess: a population-based study. Aliment Pharmacol Ther. 2015; 41(11):1175–81 (*corresponding author, 2021 IF=9.524, Rank: 17/279, pharmacology & pharmacy)

24. Lin YT, Huang YW, Chen SJ, Chang CW, Yang TC. SmeYZ Efflux Pump of Stenotrophomonas maltophilia Contributes to Drug Resistance, Virulence-related Characteristics, and Virulence in Mice. Antimicrob Agents Chemother. 2015; 59(7):4067-73. (2021 IF=5.938, Rank 51/276, pharmacology & pharmacy)

25. Lin YT, Pan YJ, Lin TL, Fung CP, Wang JT. Transfer of CMY-2 Cephalosporinase from Escherichia coli to virulent Klebsiella pneumoniae Causing a Recurrent Liver Abscess. Antimicrob Agents Chemother. 2015; 59(8):5000-2. (2021 IF=5.938, Rank 51/276, pharmacology & pharmacy)

26. Lin YT, Chuang C, Su CF, Chan YJ, Wang LS, Huang CT, Chuang YC, Siu LK, Fung CP. Efficacy of Appropriate Antimicrobial Therapy on the Survival of Patients with Carbapenem Nonsusceptible Klebsiella pneumoniae Infection: A Multicenter Study in Taiwan. Medicine. 2015; 94(33):e1405. (2021 IF=1.817, Rank: 134/329, medicine, general & internal)

27. Chiou YW, Lin YT*. Gas-forming Klebsiella pneumoniae liver abscess in a patient without diabetes. J Microbiol Immunol Infect. 2015; 48(6):709-10. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

28. Lin YT*, Huang YW, Huang HH, Yang TC, Wang FD, Fung CP. In vivo evolution of tigecycline- non-susceptible Klebsiella pneumoniae strains in patients: relationship between virulence and resistance. Int J Antimicrob Agents. 2016; 48(5):485-491. (*corresponding author, 2021 IF=15.441, Rank 11/94, infectious diseases)

29. Juan CH, Huang YW, Lin YT*, Yang TC, Wang FD. Risk factors, Outcomes and Mechanisms of Tigecycline nonsusceptible Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2016; 60(12):7357-7363. (*corresponding author, 2021 IF=5.938, Rank 51/276, pharmacology & pharmacy)

30. Wu PF, Chuang C, Su CF, Lin YT*, Chan YJ, Wang FD, Chuang YC, Siu LK, Fung CP. High minimum inhibitory concentration of imipenem as a predictor of fatal outcome in patients with carbapenem non-susceptible Klebsiella pneumoniae. Sci Rep. 2016; 6:32665. (*corresponding author, 2021 IF=4.996, Rank: 19/73, multidisciplinary sciences)

31. Yang HS, Fang WL, Lin YT*. A case of liver abscess caused by tigecycline-nonsusceptible Klebsiella pneumoniae. J Microbiol Immunol Infect. 2016; 49(4):621-2. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

32. Chuang C, Fan WC, Lin YT*, Wang FD. The emergence of Klebsiella pneumoniae liver abscess in non-diabetic patients and the distribution of capsular types. Gut Pathogens. 2016; 8:46. (*corresponding author, 2021 IF=5.324, Rank 44/136, microbiology)

33. Huang YC, Huang YW, Lin YT*, Wang FD, Chan YJ, Yang TC. Risk factors and outcome of levofloxacin-resistant Elizabethkingia meningoseptica bacteraemia in adult patients in Taiwan. Eur J Clin Microbiol Infect Dis. 2017; 36(8):1373-1380. (*corresponding author, 2021 IF=5.103, Rank 49/136, microbiology)

34. Lin YT. What can we learn from the dissemination of carbapenem-resistant Acinetobacter baumannii in patients with burn injury? J Chin Med Assoc. 2017; 80(4):189-190. (2021 IF=3.396, Rank: 71/172, medicine, general & internal)

35. Huang YC, Lin YT*, Wang FD. Comparison of the therapeutic efficacy of fluoroquinolone and non-fluoroquinolone treatment in patients with Elizabethkingia meningoseptica bacteraemia. Int J Antimicrob Agents. 2018; 51(1):47-51. (*corresponding author, 2021 IF=15.441, Rank 11/94, infectious diseases)

36. Su CF, Chuang C, Lin YT*, Chan YJ, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP. Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan. Eur J Clin Microbiol Infect Dis. 2018; 37(4):651-659. (*corresponding author, 2021 IF=5.103, Rank 49/136, microbiology)

37. Wu PF, Lin YT*, Wang FD, Yang TC, Fung CP. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia? Infection. 2018; 46(3):365-373 (*corresponding author, 2021 IF=7.455, Rank 21/94, infectious diseases)

38. Wu PS, Chuang C, Wu PF, Lin YT*, Wang FD. Anaerobic coverage as definitive therapy does not affect clinical outcomes in community-onset bacteremic biliary tract infection without anaerobic bacteremia. BMC Infect Dis. 2018; 18(1):277. (*corresponding author, 2021 IF=3.670, Rank 60/94, infectious diseases)

39. Huang YH, Chou SH, Liang SW, Ni CE, Lin YT*, Huang YW, Yang TC. Emergence of an XDR and carbapenemase-producing hypervirulent Klebsiella pneumoniae strain in Taiwan. J Antimicrob Chemother. 2018; 73(8):2039-2046. (*corresponding author, 2021 IF=5.758, Rank 54/279, Pharmacology & Pharmacy)

40. Lin YT*, Cheng YH, Juan CH, Wu PF, Huang YW, Chou SH, Yang TC, Wang FD. High mortality among patients infected with hypervirulent antimicrobial-resistant capsular type K1 Klebsiella pneumoniae strains in Taiwan. Int J Antimicrob Agents. 2018; 52(2):251-257. (*corresponding author, 2021 IF=15.441, Rank 11/94, infectious diseases)

41. Lin YT*, Su CF, Chuang C, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP. Appropriate Treatment for Bloodstream Infections Due to Carbapenem-Resistant Klebsiella pneumoniae and Escherichia coli: A Nationwide Multicenter Study in Taiwan. Open Forum Infect Dis. 2019; 6(2):ofy336. (*corresponding author, 2021 IF=4.423, Rank 61/136, microbiology)

42. Juan CH, Chuang C, Chen CH, Li L, Lin YT*. Clinical characteristics, antimicrobial resistance and capsular types of community-acquired, healthcare-associated, and nosocomial Klebsiella pneumoniae bacteremia. Antimicrob Resist Infect Control. 2019; 8:1. (*corresponding author, 2021 IF=6.459, Rank 38/210, Public, Environmental & Occupational Health)

43. Huang YC, Wu PF, Lin YT*, Wang FD. Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center. J Microbiol Immunol Infect. 2019; 52(2):304-311. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

44. Liao YT, Ko PS, Lin YT*. The first case of Klebsiella pneumoniae liver abscess with hemophagocytic lymphohistocytosis. J Microbiol Immunol Infect 2019; 52(2):363-364. (*corresponding author, 2021 IF=10.273, Rank 17/136, microbiology)

45. Juan CH, Fang SY, Chou CH, Tsai TY, Lin YT*. Clinical characteristics of patients with pneumonia caused by Klebsiella pneumoniae in Taiwan and prevalence of antimicrobial-resistant and hypervirulent strains: a retrospective study. Antimicrob Resist Infect Control. 2020; 9:4. (*corresponding author, 2024 IF=4.4, Rank 43/419, public, environmental & occupational health)

46. Cheng YH, Huang TW, Juan CH, Chou SH, Tseng YY, Chen TW, Yang TC, Lin YT*. Tigecycline-non-susceptible hypervirulent Klebsiella pneumoniae strains in Taiwan. J Antimicrob Chemother. 2020; 75(2):309-317. (*corresponding author, 2024 IF=3.6, Rank 36/137, infectious diseases)

47. Lin YT*, Cheng YH, Chuang C, Chou SH, Liu WH, Huang CH, Yang TC, Kreiswirth BN, Chen L. Molecular and Clinical Characterization of Multidrug-Resistant and Hypervirulent Klebsiella pneumoniae Strains from Liver Abscess in Taiwan. Antimicrob Agents Chemother. 2020; 64(5):e00174-20. (*corresponding author, 2024 IF=4.5, Rank 64/352, pharmacology & pharmacy)

48. Chuang C, Chou SH, Wang FD, Huang YH, Tsai TH, Lin YT*. Fluoroquinolones as an alternative treatment for Klebsiella pneumoniae liver abscess and impact on hospital length of stay. Int J Antimicrob Agents. 2020 Oct;56(4):106120. (*corresponding author, 2024 IF=4.6, Rank 17/137, infectious diseases)

49. Chen KL, Wang SJ, Chuang C, Huang LY, Chiu FY, Wang FD, Lin YT*, Chen WM. Novel Design for Door Handle-A Potential Technology to Reduce Hand Contamination in the COVID-19 Pandemic. Am J Med. 2020; 133(11):1245-1246. (2024 IF=5.3, Rank: 32/332, medicine, general & internal)

50. Chuang C, Su CF, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP, Lin YT*. Does Antimicrobial Therapy Affect Mortality of Patients with Carbapenem-Resistant Klebsiella pneumoniae Bacteriuria? A Nationwide Multicenter Study in Taiwan. Microorganisms. 2020 Dec 19;8(12):2035. (*corresponding author, 2024 IF=4.2, Rank 46/163, microbiology)

51. Chen IR, Huang PH, Wu PF, Wang FD, Lin YT*. Clinical characteristics and outcomes of 56 patients with pneumonia caused by carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2021 May 4;25:326-330. (*corresponding author, 2024 IF=3.2, Rank 43/137, infectious diseases)

52. Huang PH, Cheng YH, Chen WY, Juan CH, Chou SH, Wang JT, Chuang C, Wang FD, Lin YT*. Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae. Int J Antimicrob Agents. 2021 Jun;57(6):106342. (*corresponding author, 2024 IF=4.6, Rank 17/137, infectious diseases)

53. Cheng YH, Chou SH, Huang PH, Yang TC, Juan YF, Kreiswirth BN, Lin YT*, Chen L. Characterization of a mcr-1 and CRISPR-Cas System Co-harboring Plasmid in a Carbapenemase-Producing High-Risk ST11 Klebsiella pneumoniae Strain. Front Microbiol. 2021; 12:762947. (*corresponding author, 2024 IF=4.5, Rank: 38/163, microbiology)

54. Chen IR, Lin SN, Wu XN, Chou SH, Wang FD, Lin YT*. Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused by Klebsiella pneumoniae. Front Cell Infect Microbiol. 2022 Jun 23;12:903682. (*corresponding author, 2024 IF=4.8, Rank 32/163, microbiology)

55. Huang PH, Chen WY, Chou SH, Wang FD, Lin YT*. Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Microbiol Spectr. 2022 Jun 29;10(3):e0038122. (*corresponding author, 2024 IF=3.8, Rank 58/163, microbiology)

56. Juan CH, Chou SH, Chen IR, Yang CI, Lin YT*, Chen L. Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant Klebsiella pneumoniae strains upon hospital admission in a general ward in Taiwan. Int J Antimicrob Agents. 2022 Aug;60(2):106624. (*corresponding author, 2024 IF=4.6, Rank 17/137, infectious diseases)

57. Huang SF, Ying-Jung Wu A, Shin-Jung Lee S, Huang YS, Lee CY, Yang TL, Wang HW, Chen HJ, Chen YC, Ho TS, Kuo CF, Lin YT*; GREAT working group. COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis. J Microbiol Immunol Infect. 2023 Jun;56(3):442-454. (*corresponding author, 2024 IF=3.7, Rank 35/137, infectious diseases)

58. Chuang C, Lee KC, Wang YP, Lee PC, Chang TE, Huang YH, Lin YT*, Hou MC. High carriage rate of extended-spectrum β-lactamase Enterobacterales and diarrheagenic Escherichia coli in healthy donor screening for fecal microbiota transplantation. Eur J Clin Microbiol Infect Dis. 2023 Sep;42(9):1103-1113. (*corresponding author, 2024 IF=3, Rank 48/137, infectious diseases)

59. Wu HY, Lin YT, Tsai WC, Chiu YL, Ko MJ, Yang JY, Pai MF, Hsu HS, Hsu SP, Peng YS, Liao CH. Microbiota analysis in the hemodialysis population - Focusing on Enterobacteriaceae. J Microbiol Immunol Infect. 2023 Apr;56(2):311-323. (equal first author, 2024 IF=3.7, Rank 35/137, infectious diseases)

60. Lai YH, Lee YC, Chen IR, Lin SN, Chang YL, Lu CC, Wu PF, Lin YT*. Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan. J Microbiol Immunol Infect. 2023 Dec;56(6):1207-1213. (*corresponding author, 2024 IF=3.7, Rank 35/137, infectious diseases)

61. Lin YT, Chuang C, Chou SH, Juan CH, Yang TC, Kreiswirth BN, Chen L. Emergence of OXA-48-producing hypervirulent Klebsiella pneumoniae strains in Taiwan. Eur J Clin Microbiol Infect Dis. 2024 Feb;43(2):389-393. (2024 IF=3, Rank 48/137, infectious diseases)

62. Chang MC, Wu PF, Ho YC, Lin WY, Wu CY, Liu SY, Liu CJ, Lin YT*. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment. J Infect Public Health. 2024 Jul;17(7):102460. (*corresponding author, 2024 IF=4, Rank 57/419, public, environmental & occupational health)

63. Chou SH, Chuang C, Juan CH, Ho YC, Liu SY, Chen L, Lin YT*. Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan. Int J Antimicrob Agents. 2024 Aug;64(2):107244. (*corresponding author, 2024 IF=4.6, Rank 17/137, infectious diseases) 

64. Lu CT, Fang TP, Hung MS, Lin YT*. Clinical outcomes in ventilator
associated pneumonia patients with and without chronic obstructive pulmonary 
disease: A retrospective observational study. J Chin Med Assoc. 2025 Jan 1; 88(1):65-70. (*corresponding author, 2024 IF=2.4, Rank: 78/332, medicine, general & internal)

65. Chuang C, Kao TC, Juan CH, Chou SH, Ho YC, Liu SY, Huang YR, Ho HL, Lin YT*. Clinical Characteristics of Patients Who Acquired Gram-Negative Bacteria During Ceftazidime-Avibactam Therapy. Infect Dis Ther. 2025 May;14(5):1027-1042. (*corresponding author, 2024 IF=5.3, Rank 14/137, infectious diseases)

66. Liu SY, Chou SH, Chuang C, Juan CH, Ho YC, Ho HL, Chen L, Lin YT*. Clinical and Microbiological characteristics of patients with ceftazidime/avibactam-resistant Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae strains. Ann Clin Microbiol Antimicrob. 2025 Apr 18;24(1):26. (*corresponding author, 2024 IF=3.6, Rank 64/163, microbiology)

67. Ho YC, Chang MC, Lin WY, Wu CY, Liu SY, Chuang C, Juan CH, Liu CJ, Lin YT*. Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan. J Infect Public Health. 2025 May;18(5):102705. (*corresponding author, 2024 IF=4, Rank 57/419, public, environmental & occupational health)

68. Lin YT*, Lin SN, Chuang C, Liu SY, Ho YC, Juan CH, Ho HL, Chou SH. Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia. J Infect Public Health. 2025 Sep;18(9):102836. (*corresponding author, 2024 IF=4, Rank 57/419, public, environmental & occupational health)

69. Liu SY, Chuang C, Juan CH, Ho YC, Chou SH, Huang YR, Chin W, Ho HL, Lin YT*. Comparison of Effectiveness between Ceftazidime/Avibactam and Other Active Therapies for Oxacillinase-48-Producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Taiwan. Infect Dis Ther. 2025 Sep;14(9):2143-2156. (*corresponding author, 2024 IF=5.3, Rank 14/137, infectious diseases)

70. Juan CH, Chou SH, Chuang C, Lin SN, Wu XN, Liu SY, Ho YC, Lin YT*. Carbapenems versus non-carbapenems as definitive treatment for hypervirulent Klebsiella pneumoniae bacteremia in Taiwan. Antimicrob Agents Chemother. 2025 Dec 10;69(12):e0084625. (*corresponding author, 2024 IF=4.5, Rank 64/352, pharmacology & pharmacy)

71. Wu CY, Liu SY, Ho YC, Lin WY, Chang MC, Liu CJ, Lin YT*. Prognostic factors for mortality and respiratory failure in hospitalized patients with COVID-19 after three-dose vaccination: a retrospective cohort study during the Omicron period. BMC Infect Dis. 2026;26:196. (*corresponding author, 2024 IF=3.0, Rank 48/137, infectious diseases)